Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melanoma and pregnancy.

E C Borden1

  • 1Taussig Cancer Center, Cleveland Clinic Foundation, OH 44195, USA.

Seminars in Oncology
|December 29, 2000
PubMed
Summary

Pregnancy does not affect melanoma prognosis; however, delayed diagnosis in pregnant women necessitates prompt biopsy for suspicious moles. Management for pregnant patients should align with non-pregnant melanoma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth.

Oncogene·2012
Same author

G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer.

Oncogene·2011
Same author

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.

British journal of cancer·2011
Same author

Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.

Oncogene·2007
Same author

Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.

Clinical pharmacology and therapeutics·2007

Area of Science:

  • Dermatology
  • Obstetrics & Gynecology
  • Oncology

Background:

  • Melanoma prognosis is primarily determined by disease stage at diagnosis, independent of pregnancy status.
  • Pregnant women may experience delayed melanoma diagnosis, potentially impacting outcomes.
  • Current evidence does not link pregnancy hormones to melanoma development or recurrence risk.

Purpose of the Study:

  • To clarify the influence of pregnancy on melanoma prognosis and management.
  • To provide evidence-based recommendations for melanoma care in pregnant women.
  • To address concerns regarding hormonal influences and recurrence risk in pregnancy.

Main Methods:

  • Review of existing literature on melanoma in pregnancy.
  • Analysis of prognostic factors in pregnant versus non-pregnant melanoma patients.
  • Evaluation of evidence for hormonal influences and metastatic risk during pregnancy.

Main Results:

  • Disease stage at diagnosis is the sole consistent prognostic factor, not pregnancy itself.
  • Suspicious nevi during pregnancy require immediate biopsy, not delayed evaluation.
  • No clear hormonal factors influencing melanoma development or increased recurrence risk with subsequent pregnancies were identified.
  • Placental or fetal metastasis is rare, primarily occurring with widespread disease.

Conclusions:

  • Melanoma management in pregnant women should mirror that of non-pregnant individuals.
  • Prompt biopsy of suspicious skin lesions is crucial during pregnancy.
  • Decisions regarding future childbearing should be based on individual prognosis and personal choice.
  • Therapeutic abortion is generally not medically indicated for melanoma in pregnancy, except possibly in cases of distant metastasis.

Related Experiment Videos